# Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

> **NCT04624633** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jennifer R. Brown, MD, PhD** · enrollment: 29 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Relapsed Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Umbralisib
- **DRUG:** Ublituximab

## Key facts

- **NCT ID:** NCT04624633
- **Lead sponsor:** Jennifer R. Brown, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-15
- **Primary completion:** 2023-12-21
- **Final completion:** 2028-01-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04624633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04624633, "Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04624633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*